|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
Consistent with our previous observations, adoptive transfer of TGFβ-insensitive CD8<sup>+</sup> T cells led to the near complete regression of neoplastic disease <i>in vivo</i> However, we demonstrate that this cannot be recapitulated via global reduction in TGFβ signaling, through either genetic ablation or pharmacologic inhibition of TGFBR1.
|
30587556 |
2019 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
Lung cancer deficient in the tumor suppressor GATA4 is sensitive to TGFBR1 inhibition.
|
30971692 |
2019 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
Noncanonical TGFβ Pathway Relieves the Blockade of IL1β/TGFβ-Mediated Crosstalk between Tumor and Stroma: TGFBR1 and TAK1 Inhibition in Colorectal Cancer.
|
30979739 |
2019 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
Here, we report that human fibroblasts were induced to show osteoblast phenotypes by culturing with ALK5 i II, which is a specific inhibitor for activin-like kinase 5 (ALK5) (tumor growth factor-β receptor 1 (TGF-β R1)).
|
29855543 |
2018 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
As expected, dasatinib and anti-CTLA4 synergistically inhibited tumor growth in Tgfbr1/Pten 2cKO mice.
|
29955905 |
2018 |
|
Neoplasms
|
0.200 |
AlteredExpression
|
group |
BEFREE |
In multiple human cancers, Tβ4 levels correlate positively with TGFβ1 and the tumor-associated gene expression levels through processes that respectively depend on TGFβ receptor 1 (TGFBR1) and MRTF expression.
|
29330296 |
2018 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
Mice harboring constitutively active TGFBR1 in the testes developed tumors resembling testicular GrCTs, a rare type of tumors in the testis.
|
29788434 |
2018 |
|
Neoplasms
|
0.200 |
AlteredExpression
|
group |
BEFREE |
Also, miR-27a-agomir slows down the growth of subcutaneous HeLa xenografts and downregulates the TGF-βRI expression and TGF-β signaling in tumor in vivo.
|
29531222 |
2018 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
We showed that miR-3607-3p agomir could reduce tumor growth and inhibit TGFBR1 and CCNE2 protein expression.
|
30557355 |
2018 |
|
Neoplasms
|
0.200 |
AlteredExpression
|
group |
BEFREE |
TGFB1 and TGFBR1 mRNA expression was determined for 249 primary neuroblastoma tumors by microarray analysis.
|
27756784 |
2017 |
|
Neoplasms
|
0.200 |
AlteredExpression
|
group |
BEFREE |
In vivo experiments revealed that sitagliptin treatment reduced tumor growth and xenograft transforming growth factor-β receptor I expression.
|
28575350 |
2017 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
Herein, the possible correlation between ALK5 full length (ALK5-FL) and ALK5-ICD protein, phosphorylated Smad2/3 (pSmad2/3), and expression of TGF-β target gene PAI-1, was investigated in a clinical ccRCC material, in relation to tumor grade, stage, size and cancer specific survival.
|
27166254 |
2016 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
We also define a functional role by which the CEA B3 domain interacts with TGFBR1, potentially inactivating the tumor suppressor function of TGF-β signaling.
|
27100181 |
2016 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
Importantly, TGF-β1 increases lymphangiogenic genes and amphiregulin expression in KRC PCCs but not in murine PCCs that lack SMAD4, and combinatorial targeting of the TGF-β type I receptor (TβRI) with LY2157299 and EGFR/HER2 with lapatinib suppresses tumor growth and metastasis in a syngeneic orthotopic model, and attenuates tumor lymphangiogenesis and angiogenesis while reducing lymphangiogenic genes and amphiregulin and enhancing apoptosis.
|
27267807 |
2016 |
|
Neoplasms
|
0.200 |
AlteredExpression
|
group |
BEFREE |
Immunohistochemistry of HCC specimens showed that compared with K19(-) patients, K19(+) patients had significantly poorer recurrence-free survival and higher tumor TGFbR1 expression.
|
25820415 |
2015 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
TRAF6 also contributes to activation of TNF-α-converting enzyme and presenilin-1, resulting in the proteolytic cleavage of TβRI and releasing the intracellular domain of TβRI, which is translocated to the nucleus to promote tumor invasiveness.
|
25622187 |
2015 |
|
Neoplasms
|
0.200 |
AlteredExpression
|
group |
BEFREE |
Knockdown of Akt1 induced the expression of CDKN2B, a tumor suppressor gene, and reduced the expression of TGFBR1, which supports malignant phenotypes.
|
26315674 |
2015 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
Using an angiogenesis focused real-time array TGFA, TGFB2 and TGFBR1 and VEGFC were identified as potential candidates for hormone-influenced growth regulation of tumors in the presence of benign and high-grade stromal cells.
|
25976290 |
2015 |
|
Neoplasms
|
0.200 |
AlteredExpression
|
group |
BEFREE |
These mutations, in genes such as AKT2, CCNA1, MAP3K4, and TGFBR1, were associated significantly with EBV-positive gastric tumors, compared with EBV-negative tumors.
|
25173755 |
2014 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
Loss of heterozygosity in tumours reveals that TGFBR1 acts as a tumour suppressor gene.
|
24747516 |
2014 |
|
Neoplasms
|
0.200 |
AlteredExpression
|
group |
BEFREE |
The mRNA expression level of tumor protein T53 and transforming growth factor beta receptor 1 were found significantly reduced in critically ill patients, whereas the expression of Janus kinase 2, caspase 3 apoptosis-related cysteine peptidase, interleukin 10, and myxovirus resistance 1 were extremely increased in critically ill patients.
|
23731466 |
2013 |
|
Neoplasms
|
0.200 |
GeneticVariation
|
group |
BEFREE |
Tgfbr1 and Pten conditonal deletion (2cKO) mice were treated with rapamycin before or after the onset of HNSCC, and the efficacy of this treatment was assessed by determining tumor burden, longevity, and molecular analysis of the mTOR pathway.
|
22859719 |
2012 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
Molecular analysis revealed enhanced cell proliferation, decreased apoptosis, and increased expression of CCND1 in the basal layer of the head and neck epithelia, as well as in the tumors of Tgfbr1/Pten double conditional knockout (2cKO) mice.
|
22037217 |
2012 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
In conclusion, our results shed light on the high frequency of TGFBR1 ASE phenotype in NSCLC tumors, which is associated with the 2-tSNP haplotype of the TGFBR1 gene.
|
21225232 |
2011 |
|
Neoplasms
|
0.200 |
GeneticVariation
|
group |
BEFREE |
Further analysis showed that TGFBR1*6A genotypes were not associated with gender, age, or tumor location.
|
20429896 |
2010 |